Table 2.
Off-label use of tocilizumab in pediatric patients with JIA-associated uveitis
| Authors, year (ref.) | Sex | Age at onset, years | Age at TCZ, years | Previous therapy | Dose of TCZ | Efficacy of TCZ | Duration of TCZ | Adverse effect of TCZ |
|---|---|---|---|---|---|---|---|---|
| Tsang et al., 2014 [60] | M | 3 | 12 | GC, MTX, ADA, RTX | 8 mg/kg/2–4 weeks | Quiescence of uveitis | 20 weeks | Neutropenia when infused every 2 weeks |
| Tappeiner et al., 2016 [58] | F:M 14:3 | 15.3 ± 6.9 | GC, MTX, ≥1 TNF-α inhibitor | Inactive in 10, persisted in 7 | 5.7 months | No | ||
| Calvo-Rio et al., 2017 [57] | F:M 21:4 | 18.5 ± 8.3 (8–38) | GC, MTX, IFX, ETN, ADA, GLM, ABA, ANK, RTX | 8 mg/kg/2, 4, 8 weeks | Inactive in 19 cases | 5.5–24 months | Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), Viral conjunctivitis and bullous impetigo (1) | |
| 162 mg/week SC | ||||||||
| Quesada-Masachs et al., 2017 [62] | F | 1.9 | 14 | MTX, leflunomide, ADA | 8 mg/kg/month switching to 162 mg/week SC | Ocular flare after 6 months | 6 months | No |
TCZ tocilizumab, GC glucocorticoids, MTX methotrexate, ADA adalimumab, RTX rituximab, TNF tumor necrosis factor, IFX infliximab, ETN etanercept, GLM golimumab, ABA abatacept, ANK anakinra